Companies American Well
American Well (AMWL): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me American Well’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO vs. named peers31st pct.Of 15 peer CEOs
CEO pay, last three years
- $797,800FY2023
- $2,115,004FY2024
- $4,162,171FY2025
CEO total pay was $4,162,171 in fiscal 2025, up from $2,115,004 in fiscal 2024.
FY2025: salary $701,755 · bonus $0 · stock awards $1,294,331 · option awards $0
Executives and directors
Dmitry Zamansky · ExecutiveIdo Schoenberg · CEOMark Hirschhorn · CFODeborah Jackson · Independent DirectorDelos Cosgrove · Independent DirectorDerek Ross · Independent DirectorPeter Slavin · Independent DirectorRivka Goldwasser · Independent DirectorRob Webb · Independent DirectorStephen Schlegel · Independent Director
Frequently asked questions
Who was the highest-paid executive at American Well in fiscal 2025?
As disclosed, Ido Schoenberg (Chairman, Chief Executive Officer) was the highest-paid executive at American Well in fiscal 2025, with total compensation of $4,162,171.
How does American Well's chief executive pay compare to its disclosed peer group?
As disclosed, Ido Schoenberg's total compensation ranked at the 31st percentile of American Well's disclosed peer group.
How did shareholders vote on American Well's executive compensation?
As disclosed, 100% of shareholders supported American Well's executive compensation in the latest say-on-pay vote.
How much does American Well spend in total on board compensation for fiscal 2025?
As disclosed, American Well reported total board compensation of $1,694,755 for fiscal 2025.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Ido Schoenberg | $701,755 | $0 | $1,294,331 | $0 | $2,010,100 | $0 | $155,985 | $4,162,171 |
| Chairman, Chief Executive Officer | ||||||||
| Dan Zamansky | 401,058 | 100,000 | 2,199,606 | 0 | 502,560 | 0 | 10,500 | 3,213,724 |
| Executive Vice President, Chief Product and Technology Officer | ||||||||
| Mark Hirschhorn | 575,000 | 0 | 0 | 0 | 1,994,677 | 0 | 10,500 | 2,580,177 |
| Executive Vice President, Chief Financial Officer and Chief Operating Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Ido Schoenberg | $4,162,171 | $2,115,004 | $797,800 | ↑ +2,047,167 |
| Dan Zamansky | 3,213,724 | — | — | — |
| Mark Hirschhorn | 2,580,177 | 2,884,428 | — | ↓ −304,251 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The Committee believes that a well-designed compensation program should align the NEOs interests with Company growth and stockholder returns. Specifically, the Committee believes that the program should support and incentivize the executive team to ensure the Company s achievement of its primary business goals and allow the Company to attract and retain executives whose talents, expertise, leadership and contributions are expected to build and sustain growth in long-term stockholder value. As a result, we maintain a strong pay-for-performance orientation in our compensation program.
| CEO STI target (% of salary) | 150% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | True |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Dan Zamansky | PRSU | — | — | — | — | — | $2,199,606 |
| Ido Schoenberg | PRSU | — | — | — | — | — | 1,294,331 |
Vehicle mix — grant-date fair value by award type
Grant-level vehicle detail not disclosed.
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Schoenberg | PSU | 33,333 | — | $163,665 |
| Schoenberg | RSU | 50,000 | — | 245,500 |
| Schoenberg | PSU | 100,000 | — | 2,537,500 |
| Dan Zamansky | RSU | 165,633 | — | 813,258 |
| Mark Hirschhorn | RSU | 190,670 | — | 936,190 |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Stephen SchlegelIndependent · Audit (Chair) · Compensation (Chair) · Nominating and Corporate Governance | $85,000 | $205,291 | $0 | $0 | $0 | $290,291 |
| Rivka GoldwasserIndependent · Audit · Nominating and Corporate Governance (Chair) | 80,000 | 179,629 | 0 | 0 | 0 | 259,629 |
| Delos CosgroveIndependent · Nominating and Corporate Governance | 75,000 | 153,967 | 0 | 0 | 0 | 228,967 |
| Rob WebbIndependent · Audit · Compensation | 75,000 | 153,967 | 0 | 0 | 0 | 228,967 |
| Derek RossIndependent · Audit | 75,000 | 153,967 | 0 | 0 | 0 | 228,967 |
| Peter SlavinIndependent · Compensation · Nominating and Corporate Governance · Not standing for re-election | 75,000 | 153,967 | 0 | 0 | 0 | 228,967 |
| Deborah JacksonIndependent · Nominating and Corporate Governance | 75,000 | 153,967 | 0 | 0 | 0 | 228,967 |
| Roy SchoenbergEmployee director | 0 | 0 | 0 | — | 0 | 0 |
| Ido SchoenbergEmployee director · Board Chair | 0 | 0 | 0 | — | 0 | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $75,000 |
|---|---|
| Annual equity retainer | $150,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 5,000 / 5,000 / 5,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $540,000 |
| Equity awards (grant-date value) | $1,154,755 |
| All other compensation | $0 |
| Total cost of the board | $1,694,755 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names American Well as a peer
Companies that benchmark against AMWL
6 companies name AMWL as a compensation peer
- Accolade, Inc.ACCDFY2024
- Chrome Holding Co.MEFY2024
- DocGo Inc.DCGOFY2025
- Health Catalyst, Inc.HCATFY2025
- OptimizeRx CorpOPRXFY2025
Each company listed discloses AMWL in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named AMWL in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Disclosed peer group — fiscal year 2025
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
OMCL Omnicell, Inc.LFST LifeStance Health Group, Inc. Schrödinger, Inc.DOCS Doximity, Inc.TALK Talkspace, Inc.ACCD Accolade, Inc.PGNY Progyny, Inc.GDRX GoodRx Holdings, Inc.CERT Certara, Inc.HCAT Health Catalyst, Inc.PHR Phreesia, Inc.TDOC Teladoc Health, Inc.DH Definitive Healthcare Corp.TBRG TruBridge, Inc.LPSN LivePerson, Inc.
Peer reciprocity
Of the companies American Well names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
— Omnicell, Inc. (OMCL)58— LifeStance Health Group, Inc. (LFST)59— Doximity, Inc. (DOCS)60 Talkspace, Inc. (TALK)✓ Accolade, Inc. (ACCD)61— Progyny, Inc. (PGNY)62— GoodRx Holdings, Inc. (GDRX)63— Certara, Inc. (CERT)64✓ Health Catalyst, Inc. (HCAT)65— Phreesia, Inc. (PHR)66— Teladoc Health, Inc. (TDOC)67— Definitive Healthcare Corp. (DH)68— TruBridge, Inc. (TBRG)69— LivePerson, Inc. (LPSN)70
Reciprocity shown where the peer’s own current proxy has been read — each mark is cited in the register to that peer’s filing. A dash means the peer’s current proxy was read and names no reciprocal group including American Well.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | GoodRx Holdings, Inc. | 2025 | Wendy Barnes | $825,000 | $10,921,182 | $9,000,000 | $0 | $23,367,483 |
| 2 | Doximity, Inc. | 2026 | Jeff Tangney | 627,000 | 18,955,899 | 0 | 0 | 19,586,169 |
| 3 | Teladoc Health, Inc. | 2025 | Charles Divita, III | 800,000 | 9,699,996 | 0 | 584,000 | 11,202,996 |
| 4 | Definitive Healthcare Corp. | 2025 | Kevin Coop | 500,000 | 7,696,741 | 0 | 384,875 | 8,604,138 |
| 5 | Phreesia, Inc. | 2026 | Chaim Indig | 515,000 | 7,562,706 | 0 | 0 | 8,077,706 |
| 6 | Omnicell, Inc. | 2025 | Randall Lipps | 846,891 | 5,219,576 | 0 | 1,411,485 | 7,531,852 |
| 7 | Progyny, Inc. | 2025 | Peter Anevski | 870,000 | 3,499,980 | 2,099,995 | 736,890 | 7,220,612 |
| 8 | LifeStance Health Group, Inc. | 2025 | David Bourdon | 657,692 | 5,257,623 | 0 | 716,065 | 6,645,380 |
| 9 | Certara, Inc. | 2025 | William Feehery | 795,675 | 4,927,502 | 0 | 747,935 | 6,491,387 |
| 10 | American Well | 2025 | Ido Schoenberg | 701,755 | 1,294,331 | 0 | 2,010,100 | 4,162,171 |
| 11 | Health Catalyst, Inc. | 2025 | Daniel Burton | 525,000 | 3,444,040 | 0 | 0 | 3,991,159 |
| 12 | Accolade, Inc. | 2024 | Rajeev Singh | 500,000 | 3,320,097 | 0 | 0 | 3,823,597 |
| 13 | TruBridge, Inc. | 2024 | Christopher L. Fowler | 618,000 | 1,292,621 | 0 | 451,140 | 2,363,761 |
| 14 | Talkspace, Inc. | 2024 | Jon Cohen | 600,000 | 385,309 | 389,059 | — | 1,893,057 |
| 15 | LivePerson, Inc. | 2025 | John Sabino | 0 | 0 | 0 | 0 | 0 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| American Well | not disclosed | PSU 45 · Cash LTI 45 · RSU 10 | No | Aon |
| Accolade, Inc. | not disclosed | PSU 50 · RSU 50 | No | FW Cook |
| Certara, Inc. | 94% | PSU 60 · RSU 40 | Yes — annualized total stockholder return (ATSR) | Meridian Compensation Partners |
| Definitive Healthcare Corp. | not disclosed | not disclosed | Yes — relative TSR | not disclosed |
| Doximity, Inc. | not disclosed | not disclosed | No | Aon plc (Human Capital Solutions Practice) |
| GoodRx Holdings, Inc. | not disclosed | not disclosed | not disclosed | Pay Governance |
| Health Catalyst, Inc. | 39% | RSU 50 · PRSU 50 | Yes — TSR Achievement | Aon |
| LifeStance Health Group, Inc. | not disclosed | not disclosed | not disclosed | Pay Governance |
| LivePerson, Inc. | not disclosed | not disclosed | not disclosed | Third-party compensation consultant |
| Omnicell, Inc. | 133.3% | RSU 50 · PSU 50 | No | Exequity |
| Phreesia, Inc. | 140.3% | PSU 50 · RSU 50 | Yes — Relative TSR | FW Cook, Inc. |
| Progyny, Inc. | 85% | RSU 40 · Options 30 · PSU 30 | No | Semler Brossy |
| Talkspace, Inc. | not disclosed | not disclosed | not disclosed | Meridian |
| Teladoc Health, Inc. | 73% | RSU 50 · PSU 50 | No | Aon |
| TruBridge, Inc. | 100% | PSU 60 · RSU 40 | No | Frederic W. Cook & Co., Inc. |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-16 | 21,137,741 | 326,662 | — | 100% | Passed |
| 2025 | 2025-06-11 | 19,633,851 | 600,985 | — | 97.03% | Passed |
| 2024 | 2024-06-18 | 384,527,467 | 7,805,571 | — | 98.01% | Passed |
| 2023 | 2023-06-22 | 343,920,194 | 34,803,341 | — | 90.81% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-06-16 | 100%a |
| 2025 | 2025-06-11 | 97.03%b |
| 2024 | 2024-06-18 | 98.01%c |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
c. Approved under the standard stated in the filing — “Abstentions will have the same effect as votes against this proposal.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | — |
|---|---|
| CEO total compensation | — |
| Median employee compensation | — |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Ido Schoenberg | Director | 2026-05-07 | A | 670 | $7 | $4,938 | Common | Form 4 ↗ |
| Paul Francis McNeice | Chief Accounting Officer | 2026-06-01 | D | 112 | 10 | 1,091 | Common | Form 4 ↗ |
| Phyllis Gotlib | President, International | 2026-06-01 | D | 3,573 | 10 | 34,801 | Common | Form 4 ↗ |
| Mark Hirschhorn | Chief Financial Officer | 2026-06-01 | D | 10,761 | 10 | 104,812 | Common | Form 4 ↗ |
| Stephen Schlegel | Director | 2026-06-11 | D | 9,750 | 9 | 85,449 | Common | Form 4 ↗ |
| Derek Ross | Director | 2026-06-16 | A | 14,501 | 0 | 0 | Common | Form 4 ↗ |
| Deborah Jackson | Director | 2026-06-16 | A | 14,501 | 0 | 0 | Common | Form 4 ↗ |
| Stephen Schlegel | Director | 2026-06-16 | A | 14,501 | 0 | 0 | Common | Form 4 ↗ |
| Rivka Goldwasser | Director | 2026-06-16 | A | 14,501 | 0 | 0 | Common | Form 4 ↗ |
| Rob Webb | Director | 2026-06-16 | A | 14,501 | 0 | 0 | Common | Form 4 ↗ |
| Delos Cosgrove | Director | 2026-06-16 | A | 14,501 | 0 | 0 | Common | Form 4 ↗ |
| Mark Hirschhorn | Chief Financial Officer | 2026-07-01 | D | 4,299 | 9 | 40,110 | Common | Form 4 ↗ |
| Paul Francis McNeice | Chief Accounting Officer | 2026-07-01 | D | 653 | 9 | 6,092 | Common | Form 4 ↗ |
| Phyllis Gotlib | President, International | 2026-07-01 | D | 6,677 | 9 | 62,296 | Common | Form 4 ↗ |
| Dan Zamansky | Chief Product & Tech. Officer | 2026-07-01 | D | 8,460 | 9 | 78,932 | Common | Form 4 ↗ |
| Paul Francis McNeice | Chief Accounting Officer | 2026-09-01 | D | 112 | 12 | 1,322 | Common | Form 4 ↗ |
| Mark Hirschhorn | Chief Financial Officer | 2026-09-01 | D | 10,751 | 12 | 126,862 | Common | Form 4 ↗ |
| Phyllis Gotlib | President, International | 2026-09-01 | D | 3,573 | 12 | 42,161 | Common | Form 4 ↗ |
| Phyllis Gotlib | President, International | 2026-10-01 | D | 6,677 | 13 | 86,801 | Common | Form 4 ↗ |
| Mark Hirschhorn | Chief Financial Officer | 2026-10-01 | D | 4,282 | 13 | 55,666 | Common | Form 4 ↗ |
| Dan Zamansky | Chief Product & Tech. Officer | 2026-10-01 | D | 8,442 | 13 | 109,746 | Common | Form 4 ↗ |
| Paul Francis McNeice | Chief Accounting Officer | 2026-10-01 | D | 653 | 13 | 8,489 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (70 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Ido Schoenberg. DEF 14A, filed 2026-04-23. Section “Summary Compensation Table” · page 29. As printed: 4,162,171. View filing ↗
- Section 01, Dan Zamansky. DEF 14A, filed 2026-04-23. Section “Summary Compensation Table”. As printed: 3,213,724. View filing ↗
- Section 01, Mark Hirschhorn. DEF 14A, filed 2026-04-23. Section “Summary Compensation Table”. As printed: 2,580,177. View filing ↗
- Section 03, Dan Zamansky PRSU. DEF 14A, filed 2026-04-23. Section “E XECUTIVE COMPENSATION” · grants of plan-based awards table. View filing ↗
- Section 03, Ido Schoenberg PRSU. DEF 14A, filed 2026-04-23. Section “E XECUTIVE COMPENSATION” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. 10-K, filed 2026-02-12. Section “CEO Pay Ratio”. As printed: —. View filing ↗
- Section 08, Stephen Schlegel. DEF 14A, filed 2026-04-23. Section “Director Compensation”. As printed: 290,291. View filing ↗
- Section 08, Rivka Goldwasser. DEF 14A, filed 2026-04-23. Section “Director Compensation”. As printed: 259,629. View filing ↗
- Section 08, Delos Cosgrove. DEF 14A, filed 2026-04-23. Section “Director Compensation”. As printed: 228,967. View filing ↗
- Section 08, Rob Webb. DEF 14A, filed 2026-04-23. Section “Director Compensation”. As printed: 228,967. View filing ↗
- Section 08, Derek Ross. DEF 14A, filed 2026-04-23. Section “Director Compensation”. As printed: 228,967. View filing ↗
- Section 08, Peter Slavin. DEF 14A, filed 2026-04-23. Section “Director Compensation”. As printed: 228,967. View filing ↗
- Section 08, Deborah Jackson. DEF 14A, filed 2026-04-23. Section “Director Compensation”. As printed: 228,967. View filing ↗
- Section 08, Roy Schoenberg. DEF 14A, filed 2026-04-23. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Ido Schoenberg. DEF 14A, filed 2026-04-23. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, Ido Schoenberg 2026-05-07. Form 4, filed 2026-05-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Paul Francis McNeice 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Phyllis Gotlib 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark Hirschhorn 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Stephen Schlegel 2026-06-11. Form 4, filed 2026-06-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Derek Ross 2026-06-16. Form 4, filed 2026-06-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Deborah Jackson 2026-06-16. Form 4, filed 2026-06-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Stephen Schlegel 2026-06-16. Form 4, filed 2026-06-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Rivka Goldwasser 2026-06-16. Form 4, filed 2026-06-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Rob Webb 2026-06-16. Form 4, filed 2026-06-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Delos Cosgrove 2026-06-16. Form 4, filed 2026-06-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark Hirschhorn 2026-07-01. Form 4, filed 2026-07-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Paul Francis McNeice 2026-07-01. Form 4, filed 2026-07-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Phyllis Gotlib 2026-07-01. Form 4, filed 2026-07-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dan Zamansky 2026-07-01. Form 4, filed 2026-07-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Paul Francis McNeice 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark Hirschhorn 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Phyllis Gotlib 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Phyllis Gotlib 2026-10-01. Form 4, filed 2026-10-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark Hirschhorn 2026-10-01. Form 4, filed 2026-10-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dan Zamansky 2026-10-01. Form 4, filed 2026-10-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Paul Francis McNeice 2026-10-01. Form 4, filed 2026-10-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-06-22. Item 5.07 · say-on-pay result. As reported: 100% (votes for as printed: 21,137,741). View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-06-17. Item 5.07 · say-on-pay result. As reported: 97.03% (votes for as printed: 19,633,851). View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-06-24. Item 5.07 · say-on-pay result. As reported: 98.01% (votes for as printed: 384,527,467). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 09b board cost (computed). Computed. Cash 540,000 + equity 1,154,755 + all other 0 = 1,694,755, summed across the director compensation table rows.
- GoodRx Holdings, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in GoodRx Holdings, Inc.'s own proxy. As printed: 23,367,483. View filing ↗
- Doximity, Inc., Section 10b CEO total. DEF 14A, filed 2026-07-15. CEO total compensation as printed in Doximity, Inc.'s own proxy. As printed: 19,586,169. View filing ↗
- Teladoc Health, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-07. CEO total compensation as printed in Teladoc Health, Inc.'s own proxy. As printed: 11,202,996. View filing ↗
- Definitive Healthcare Corp., Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Definitive Healthcare Corp.'s own proxy. As printed: 8,604,138. View filing ↗
- Phreesia, Inc., Section 10b CEO total. DEF 14A, filed 2026-05-14. CEO total compensation as printed in Phreesia, Inc.'s own proxy. As printed: 8,077,706. View filing ↗
- Omnicell, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-13. CEO total compensation as printed in Omnicell, Inc.'s own proxy. As printed: 7,531,852. View filing ↗
- Progyny, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-10. CEO total compensation as printed in Progyny, Inc.'s own proxy. As printed: 7,220,612. View filing ↗
- LifeStance Health Group, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in LifeStance Health Group, Inc.'s own proxy. As printed: 6,645,380. View filing ↗
- Certara, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-03. CEO total compensation as printed in Certara, Inc.'s own proxy. As printed: 6,491,387. View filing ↗
- American Well (subject), Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in American Well's own proxy. As printed: 4,162,171. View filing ↗
- Health Catalyst, Inc., Section 10b CEO total. DEF 14A, filed 2026-06-03. CEO total compensation as printed in Health Catalyst, Inc.'s own proxy. As printed: 3,991,159. View filing ↗
- Accolade, Inc., Section 10b CEO total. DEF 14A, filed 2024-06-21. CEO total compensation as printed in Accolade, Inc.'s own proxy. As printed: 3,823,597. View filing ↗
- TruBridge, Inc., Section 10b CEO total. DEF 14A, filed 2025-03-26. CEO total compensation as printed in TruBridge, Inc.'s own proxy. As printed: 2,363,761. View filing ↗
- Talkspace, Inc., Section 10b CEO total. DEF 14A, filed 2025-04-30. CEO total compensation as printed in Talkspace, Inc.'s own proxy. As printed: 1,893,057. View filing ↗
- LivePerson, Inc., Section 10b CEO total. DEF 14A, filed 2025-05-22. CEO total compensation as printed in LivePerson, Inc.'s own proxy. As printed: 0. View filing ↗
- Section 10a, Omnicell, Inc. reciprocity. DEF 14A. Omnicell, Inc.'s most recent proxy was read; its disclosed peer group does not include American Well. View filing ↗
- Section 10a, LifeStance Health Group, Inc. reciprocity. DEF 14A. LifeStance Health Group, Inc.'s most recent proxy was read; its disclosed peer group does not include American Well. View filing ↗
- Section 10a, Doximity, Inc. reciprocity. DEF 14A. Doximity, Inc.'s most recent proxy was read; its disclosed peer group does not include American Well. View filing ↗
- Section 10a, Accolade, Inc. reciprocity. DEF 14A. Accolade, Inc. names American Well in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Progyny, Inc. reciprocity. DEF 14A. Progyny, Inc.'s most recent proxy was read; its disclosed peer group does not include American Well. View filing ↗
- Section 10a, GoodRx Holdings, Inc. reciprocity. DEF 14A. GoodRx Holdings, Inc.'s most recent proxy was read; its disclosed peer group does not include American Well. View filing ↗
- Section 10a, Certara, Inc. reciprocity. DEF 14A. Certara, Inc.'s most recent proxy was read; its disclosed peer group does not include American Well. View filing ↗
- Section 10a, Health Catalyst, Inc. reciprocity. DEF 14A. Health Catalyst, Inc. names American Well in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Phreesia, Inc. reciprocity. DEF 14A. Phreesia, Inc.'s most recent proxy was read; its disclosed peer group does not include American Well. View filing ↗
- Section 10a, Teladoc Health, Inc. reciprocity. DEF 14A. Teladoc Health, Inc.'s most recent proxy was read; its disclosed peer group does not include American Well. View filing ↗
- Section 10a, Definitive Healthcare Corp. reciprocity. DEF 14A. Definitive Healthcare Corp.'s most recent proxy was read; its disclosed peer group does not include American Well. View filing ↗
- Section 10a, TruBridge, Inc. reciprocity. DEF 14A. TruBridge, Inc.'s most recent proxy was read; its disclosed peer group does not include American Well. View filing ↗
- Section 10a, LivePerson, Inc. reciprocity. DEF 14A. LivePerson, Inc.'s most recent proxy was read; its disclosed peer group does not include American Well. View filing ↗